BridgeMD
New treatment option for Psychosis
Official title Determining the Role of Social Reward Learning in Social Anhedonia
ClinicalTrials.gov ID: NCT05617898
What this study is testing
- What it's testing
- This is a clinical trial study that aims to evaluate the specificity of the relationship between reduced sensitivity to social reward and social anhedonia at both behavioral and neural levels. Individuals who recently experienced their first-episode psychosis will be recruited.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 35
You may be able to join if
- Age 18-35 years
- A first episode of a psychotic illness that began within the past three years
- Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder
- Taking 2nd generation antipsychotic medications
- Estimated premorbid IQ not less than 70 as assessed with the Wechsler Test of Adult Reading
You likely can't join if
- No evidence that substance use makes the diagnosis ambiguous (rule out substance-induced psychosis)
- No evidence of moderate or severe alcohol or substance use disorder in the past 3 months
- No clinically significant disease based on medical history (e.g., epilepsy) or significant head injury
- For females: no current pregnancy
- No sedatives or anxiolytics on the day of assessment
- No medication change 3 weeks prior to enrollment
See the full eligibility criteria
- Age 18-35 years
- A first episode of a psychotic illness that began within the past three years
- Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder
- Taking 2nd generation antipsychotic medications
- Estimated premorbid IQ not less than 70 as assessed with the Wechsler Test of Adult Reading
- Appropriate for scanning (i.e., no pacemaker or metal implants) and expressed willingness to participate in scanning
- Sufficient fluency in English to comprehend testing procedures
- Corrected vision of at least 20/30
- No evidence that substance use makes the diagnosis ambiguous (rule out substance-induced psychosis)
- No evidence of moderate or severe alcohol or substance use disorder in the past 3 months
- No clinically significant disease based on medical history (e.g., epilepsy) or significant head injury
- For females: no current pregnancy
- No sedatives or anxiolytics on the day of assessment
- No medication change 3 weeks prior to enrollment
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
- Los Angeles, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 35 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States; Los Angeles, California, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.